Literature DB >> 11087198

A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types.

K L Liaw1, A Hildesheim, R D Burk, P Gravitt, S Wacholder, M M Manos, D R Scott, M E Sherman, R J Kurman, A G Glass, S M Anderson, M Schiffman.   

Abstract

Human papillomavirus (HPV)-16 causes about half the cases of cervical cancer worldwide and is the focus of HPV vaccine development efforts. Systematic data are lacking as to whether the prevention of HPV-16 could affect the equilibrium of infection with other HPV types and thus alter the predicted impact of vaccination on the occurrence of cervical neoplasia. Therefore, the associations of HPV-16 detection with subsequent acquisition of other HPV types and with the persistence of concomitantly detected HPV types were examined prospectively among 1124 initially cytologically normal women. Preexisting HPV-16 was generally associated with an increased risk for subsequent acquisition of other types. HPV-16 did not affect the persistence of concomitant infections, regardless of type. These findings suggest that the prevention or removal of HPV-16 is not likely to promote the risk of infection with other types, a theoretical concern with current vaccination efforts.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11087198     DOI: 10.1086/317638

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  69 in total

1.  A Suggested Approach to Simplify and Improve Cervical Screening in the United States.

Authors:  Mark Schiffman; Nicolas Wentzensen
Journal:  J Low Genit Tract Dis       Date:  2016-01       Impact factor: 1.925

2.  Backward bifurcations and multiple equilibria in epidemic models with structured immunity.

Authors:  Timothy C Reluga; Jan Medlock; Alan S Perelson
Journal:  J Theor Biol       Date:  2008-01-26       Impact factor: 2.691

3.  Bias Due to Correlation Between Times-at-Risk for Infection in Epidemiologic Studies Measuring Biological Interactions Between Sexually Transmitted Infections: A Case Study Using Human Papillomavirus Type Interactions.

Authors:  Talía Malagón; Philippe Lemieux-Mellouki; Jean-François Laprise; Marc Brisson
Journal:  Am J Epidemiol       Date:  2016-12-07       Impact factor: 4.897

4.  Acquisition of high-risk human papillomavirus infection in a population-based cohort of Danish women.

Authors:  Ann Nielsen; Thomas Iftner; Christian Munk; Susanne K Kjaer
Journal:  Sex Transm Dis       Date:  2009-10       Impact factor: 2.830

5.  Cancer registries and monitoring the impact of prophylactic human papillomavirus vaccines: the potential role.

Authors:  Mona Saraiya; Marc T Goodman; S Deblina Datta; Vivien W Chen; Phyllis A Wingo
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

6.  Type-specific incidence, clearance and predictors of cervical human papillomavirus infections (HPV) among young women: a prospective study in Uganda.

Authors:  Cecily Banura; Sven Sandin; Leen-Jan van Doorn; Wim Quint; Bernhard Kleter; Fred Wabwire-Mangen; Edward K Mbidde; Elisabete Weiderpass
Journal:  Infect Agent Cancer       Date:  2010-04-09       Impact factor: 2.965

7.  Human papillomavirus types 16 and 18 DNA load in relation to coexistence of other types, particularly those in the same species.

Authors:  Long Fu Xi; Zoe R Edelstein; Craig Meyers; Jesse Ho; Stephen L Cherne; Mark Schiffman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-08-18       Impact factor: 4.254

8.  Model for assessing human papillomavirus vaccination strategies.

Authors:  Elamin H Elbasha; Erik J Dasbach; Ralph P Insinga
Journal:  Emerg Infect Dis       Date:  2007-01       Impact factor: 6.883

9.  Age-specific prevalence of HPV genotypes in cervical cytology samples with equivocal or low-grade lesions.

Authors:  S Brismar-Wendel; M Froberg; A Hjerpe; S Andersson; B Johansson
Journal:  Br J Cancer       Date:  2009-07-21       Impact factor: 7.640

10.  Development and validation of a HPV-32 specific PCR assay.

Authors:  Nicholas R Herrel; Nadia L Johnson; Jennifer E Cameron; Janet Leigh; Michael E Hagensee
Journal:  Virol J       Date:  2009-06-27       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.